Skip Navigation

Covid-19 Related Funding Opportunities

Skip Side Navigation

Covid-19 Related Funding Opportunities

Rolling Deadline:

Department of Energy DCL solicits ideas on how to contribute DOE resources to address COVID-19
Submissions reviewed on a Rolling Basis, starting on March 18, 2020
DOE requests input on strategic, priority research directions that may be undertaken using DOE user facilities, computational resources, and enabling infrastructure

Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) established a Commercial Solution Opening (CSO)
Solution briefs are accepted on a rolling basis through September 30, 2020
The DAF ACT seeks innovative solutions for commercial technologies that can “provide relief, resilience, recovery, and stability to the nation in response to the COVID-19 pandemic.” DAF ACT Areas of Interest include: Combating the Spread; Welfare of citizens; Readiness; Logistics; and Medical.

National Heart, Lung, and Blood Institute (NHLBI) issued a NOSI for COVID-19
Applications accepted on a Rolling Basis through October 6, 2020
Topics of specific interest include host response; associations with heart, lunch and blood diseases; potential impacts on transfusion safety; and clinical outcomes of infected individuals.

NOSI: Availability of Supplements for Research on Stress Management in Relation to COVID-19
Applications accepted on a Rolling Basis through October 6, 2020
Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

Biomedical Advanced Research and Development Authority (BARDA) at the Department of Health and Human Services (HHS) released an Easy Broad Agency Announcement for COVID-19 Diagnostics
White papers are accepted on a Rolling basis through October 31, 2020
BARDA seeks proposals for COVID-19 diagnostics that use "platforms already cleared by the U.S. Food and Drug Administration (FDA), with a viable plan to meet requirements for the FDA to consider an Emergency Use Authorization within 12 weeks of an award. Full proposals may be invited based on the submitted White Paper.

National Institute of Allergy and Infectious Disease (NIAID) COVID-19 Funding
Proposals accepted on a Rolling basis through February 6, 2021
NIAID using noncompetitive administrative supplements and competitive Urgent Awards to disperse $826 million in emergency funding.

National Institute of General Medical Sciences (NIGMS) issued NOSI for SARS-CoV-2 virus
Applications accepted on a Rolling Basis through February 6, 2021
NIGMS solicits competitive revisions that address: "incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents; repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR only); rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only)."

NIAID issues a Notice of Special Interest (NOSI) for the Availability of Emergency Competitive Revisions for Research on SARS-CoV-2 and COVID-19
Applications accepted on a Rolling Basis through March 25, 2021
The NOSI details NIAID's research priorities and urgent need for projects focused on viral natural history, pathogenicity, transmission, and projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics. Applications can request Administrative Supplements and Emergency Competitive Revisions

National Institute on Drug Abuse (NIDA) issued a NOSI for COVID-19 to collect/examine data for individuals suffering from substance use disorders (SUD)
Applications accepted on a Rolling Basis through March 31, 2021
This NOSI mentions topics of specific interest including respiratory effects of COVID-19 among individuals with SUD, drug-drug interaction of medication to treat COVID-19 and substances of abuse or medications to treat SUDs.

NOSI: Supplements for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences
Applications accepted on a Rolling Basis through March 31, 2021
This NOSI encourages supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts.

NOSI: Supplements on COVID-19 within the Mission of National Institute on Alcohol Abuse and Alcoholism (NIAAA) 
Applications accepted on a Rolling Basis through April 15, 2021
This NOSI encourages applications to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.

NOSI: Supplements for Mental Health Research related to the 2019 Novel Coronavirus
Applications accepted on a Rolling Basis through April 15, 2021
National Institute of Mental Health (NIMH) seeks research that provides evidence for how a disrupted workforce may adequately respond, adapt, and maintain services or provide additional care for new or increasing mental health needs.

NIAID Announces R01 Emergency Awards: Rapid Investigation of SARS-CoV-2 and COVID-19
R21 funding mechanism also available
Applications accepted on a Rolling Basis through April 30, 2021
NIAID intends to provide expedited funding for research on SARS-CoV-2 and COVID-19. Areas of high priority include: understanding critical aspects of viral infection/replication; critical aspects of viral transmission; development and testing of SARS-CoV-2 therapeutic candidates; and development of vaccination strategies for at-risk populations.

NIH National Institute on Aging (NIA) issued a Notice of Special Interest (NOSI) related to COVID-19 crisis
Administrative Supplements and Competitive Revision Applications accepted on a rolling basis through May 1, 2021
NIA requests applications for research interests relevant to work within Divisions of Aging Biology, Neuroscience, Geriatrics and Clinical Gerontology, and Behavioral and Social Research. The National Institute of Mental Health (NIMH) is also accepting applications to existing NIMH grants that focus on "how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or worsening mental health needs in midlife and older age adults."

NOSI: Supplements to Study the Impact of COVID-19 Outbreak on Minority Health and Health Disparities
Applications accepted on a Rolling Basis through May 1, 2021
Research is solicited in health disparity populations that -seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations.

NOSI: NIEHS seeks to understand the impact of Environmental Exposures on 2019 Coronavirus
Applications accepted on a monthly basis through May 2021
The National Institute of Environmental Health Sciences (NIEHS) seeks to understand the potential contributions of current and past exposure to environmental agents that may exacerbate COVID-19 susceptibility, disease severity, and progression. Environmental exposures include toxic chemicals, air pollutants, second hand tobacco smoke, e-cigarette vapors, and metals that may impact health outcomes. In addition, some health outcomes that are linked to environmental exposures (asthma, diabetes, and other pulmonary, cardiovascular, and metabolic diseases) are also risk factors for COVID-19. Funding through Supplements or Time-Sensitive Research (R21).

NIH Announces Rapid Acceleration of Diagnostics (RADx) program
Proposals accepted on a Rolling Basis (June 30, 2021)
The RADx program fast-tracks COVID-19 test development and distribution and will leverage the existing Point-of-Care Technology Research Network to support novel solutions to ramp up national capacity for SARS- CoV-2 testing. The RADx program will support all phases of product development from conceptualization and design through manufacturing.

EDA Releases COVID-19 CARES Act Recovery Assistance Guidelines
EDA will review submissions until NOFO is cancelled or funding expires (June 30, 2021)
EDA CARES Act funding will largely be provided through the EDA Economic Adjustment Assistance (EAA) Program, which supports a broad array of development initiatives with potential to expand economic activity and recovery. Applicants must express how their project would respond to the impacts of the pandemic and align with regional economic development plans.

Patient-Centered Outcomes Research Institute (PCORI) Solicits COVID-19 Enhancements to Existing PCORI-Funded Projects
Applications accepted on a Rolling Basis until no longer relevant (June 2021)
PCORI seeks to support work for COVID-19 related dilemmas facing patients, caregivers, providers, health systems, and policymakers through targeted investments in extending our Research, Engagement Awards, and Dissemination and Implementation activities.

National Center for Advancing Translational Sciences (NCATS) issued a NOSI for COVID-19
Applications accepted from May 4, 2020 through July 10, 2021
Research priorities include "use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines." Awards can be made through Administrative Supplements, Collaborative Innovation Awards, and Competitive Revisions.

NOSI: Supplements for Tissue Chips Research on the 2019 Novel Coronavirus
Applications accepted on a Rolling Basis through January 25, 2022
NCATS solicits research that uses microphysiological systems or tissue chips for collecting and examining data on the risks and outcomes of COVID-19 infection, in order to advance the translation of research findings into diagnostics, therapeutics, and vaccines.

NIH Solicits New National Centers for Biomedical Imaging and Bioengineering (NCBIB)
Annually: January 25, May 25, September 25 through 2023
This P41 biotechnology resource grant program solicitation intends to establish National Centers for Biomedical Imaging and Bioengineering (NCBIB) to accelerate the development and dissemination of new biomedical technology. Centers will have central Technology Research and Development projects; engage in Collaborative Projects that serve as technology drivers, users and testbeds for technology developed in TR&D projects, and Service Projects that serve as users of the well-developed and stable technologies of the Center.

HHS BARDA EZ-BAA: COVID-19 from February 5, 2020
Applications accepted on a Rolling Basis through February 3, 2023
Proposals for COVID-19 diagnostics that "utilize platforms already cleared by US FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of award."

In-Q-Tel interested in COVID-19 related technology innovations
Rolling
In-Q-Tel works to accelerate the development of cutting edge "ready-soon" technologies. Specific technologies sought to combat COVID-19 include: point-of-care diagnostics; swabs for sample collection; serological diagnostics; and digital self-triage capabilities for telehealth. 

HHS BARDA: CoronaWatch Accepting Technology Acceleration Applications
Applications accepted on a Rolling Basis
CoronaWatch used to accelerate technologies related to COVID-19
Specific submission options for therapeutics, vaccines, diagnostics, and other products.

Department of Energy releases Dear Colleague Letter soliciting ideas to address COVID-19
Applications accepted on a Rolling basis
DOE encourages the scientific community and others to consider research questions that underpin COVID-19 response and requests input on strategic, priority research directions that may be undertaken using DOE user facilities, computational resources, and enabling infrastructure.

NIH National Human Genome Research Institute (NHGRI) issues Notice of Special Interest (NOSI) to better understand SARS-CoV2
Competitive Revision Applications accepted on a Rolling Basis
This solicitation focuses on better understanding host response, associated diseases, and short- and long-term clinical outcomes of infected individuals. Interest include development of novel methods using genomic techniques to identify signatures of infection, prognosis, and severity of disease; development of novel genomic-based tools, kits or reagents to track/monitor infected individuals; and use of tools to understand genetic epidemiology of SARS-CoV-2.

NSF DCL: COVID-19 from March 4, 2020
Applications accepted on a Rolling Basis
RAPID proposals solicited to conduct "non-medical, non-clinical care research to explore how to model and understand the spread of COVID-19, inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge." Projects would be funded under existing funding opportunities.

NSF OAC DCL: COVID-19 from March 5, 2020
Applications accepted on a Rolling Basis
The Office of Advanced Cyberinfrastructure invites supplemental funding requests, RAPID proposals, and proposals to use NSF advanced cyberinfrastructure for research utilizing data or software approaches for COVID-19 related challenges. Projects would be funded under CDS&E and CSSI NSF programs.

COVID-19 HPC Consortium Created March 22, 2020
Submissions accepted on a Rolling Basis
Managed by the Extreme Science and Engineering Discovery Environment (XSEDE), the consortium will enable access to powerful and advanced computers to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines.

HHS BARDA: CoronaCoronaWatch used to accelerate technologies related to COVID-19
Submissions accepted on a Rolling Basis
Specific submission options for therapeutics, vaccines, diagnostics, and other products.

Anticipated:

NIH releases NOI for RADx funding programs
Anticipated deadlines starting in September 2020
The National Institutes of Health (NIH) intends to publish multiple funding opportunity announcements for the Rapid Acceleration of Diagnostics for Radical (RADx-rad) program from July 17-31, 2020 on topics listed below. The RADx-rad program was created to support innovative and non-traditional approaches to rapid diagnostics and home-based testing technologies. 
1. Wastewater detection of SARS-CoV-2 (COVID-19) 
2. Exosome-based non-traditional technologies toward multi-parametric and integrated approaches for SARS-CoV-2
3. Chemosensory testing as a COVID-19 screening tool
4. Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds)
5. Multimodal COVID-19 surveillance methods for High Risk Populations in densely populated facilities
6. Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 from Skin and The Oral Cavity
7. Automatic detection and tracing of SARS-CoV-2

DOD Army MTEC likely to release further COVID-19 RFPs 
Anticipated
RFPs for other topics are anticipated including: Point of care diagnostics, prophylactics/therapeutics that can prevent/treat rapidly in a non-hospital environment, disease predictive modeling, patient monitoring, tracking and management system.

EDA Previews New Funding for COVID-19 Entrepreneurship and Innovation Assistance
FOA Anticipated
EDA intends to launch a new ~$25 million funding opportunity, the Coronavirus Entrepreneurship & Innovation Challenge, a competition to address unique innovation and entrepreneurship-related challenges and opportunities associated with the pandemic, including providing support for the commercialization of new technologies to address COVID-19 and creative efforts to promote innovation activities under current conditions. Initial areas of interest include: 1) Biotechnology, Health Security, and Supply Chain Innovation; 2) Regional, National, and Government Connectivity; 3) Innovation& Entrepreneurship; and 4) Access to Capital. Details have not been finalized.

Health-related engagement opportunities:

NIAID Releases 2020-2024 Strategic Plan for COVID-19
For informational purposes
NIAID’s Strategic Plan is to “conduct and support research on SARS‐CoV‐2 and COVID‐19 to accelerate the development of safe and effective medical countermeasures that decrease disease incidence, mitigate morbidity and prevent mortality.” Four research priority pillars include: 1) Improve knowledge and understanding of SARS-CoV-2 and COVID-19; 2) Develop diagnostics and assays to identify and isolate COVID-19 cases; 3) Characterize and test potential therapeutics and treatments for COVID-19; and 4) Develop effective vaccines to combat SARS-CoV-2.

Trump Administration Adds Health Plans to June 2020 Plasma Donation Guidance
Keep until November 2020
HIPAA Privacy Rule permits a covered health care provider or health plan to use protected health information (PHI) to identify and contact individuals who have recovered from COVID-19 to provide them with information about donating plasma that could be used to help patients with COVID-19.